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Ieohemic renal disease caused by renal artery stenosis (RAS) isa potentially
treatabla condition. However, the role of intervention for RAS not associated
with hypertension or decreased renal function has not been eatsblished. In
this study we assessed the effect of RAS on renal function in 1015 consecu-
tivepetienta (maan age60+ 11yeara)whoundervventcardiaccatheterization
and abdominal aortography on ?2 occaaions at least 6 months apart (mean
2.6 + 1.7 yeare). All patients had normal renal arteries at baseline.
Resu/ts;219 patients (21.6%) had ?25%stenosis of at least 1 renal artery
at follow-up.
“ARAS n Creatinine(m@dL)
Baseline o 1015 1.07 + 0,27
Follow-uP o 798 1,12 + 0,60
25 99 1,17 * 0,64
50 62 1,10 + 0.33
75 29 1,23 + 0.40
:95 29 1.90 + 1.81’
*p= 0.03 compared to othergroups
After excluding patients with significant (>50%) contralaterel RAS, follow-
UPcreatinine (1.69 + 1.66 mg/dL) remained significantly elevated when RAS
was ?95% (n= 27, p = 0.04).
Conclusions: Progression of RAS to ?95% is associated with a signifi-
cant deterioration in renal function. Elevation in serum creatinine may occur
despite insignificant diaease in the contrelateral renal artery.
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Although multi-vessel CAD patients (pts) are frequently referred for myccar-
dial revaacularization (revasc) before peripheral vascular surgery (PVS) in
hope of reducing risk of cardiac events, little data are available to support
routine use of revasc before PVS. In a prospective study we evaluated the
safety and ( of long-acting PI selective beta-blocker, betexolol (B),
in @ucing risk of perioperative cardiac events. Ischemia was evaluated by
exerciae stress testing, Helter monitoring (HM) and dipyridamole thallium
acintigraphy. Patients with evidence of ischemia underwent angiography.
Those with ischemia and multivessel CAD (excluding left main or 3V with
LVEF < 40%) were titrated on B 10-20 mg qd for 2 wks prior to PVS. All
pta were carafully evaluated for Ml, unstable angina, shock, and serious
arrhythmias during the perioparative period. Resu/ts:34 pts underwent PVS.
24 pts received B, 10 pts not receiving B served as controls.
E C
Age, Mean ISD 66*5 67& 2
SyatolicBP.* 136 *23 132 +17
DiastolicB.P” 67* 10 77% 12
Heart Rste* 60+8 61 h 22
EjectionFraction 59 h 8 57+ 6
CAD (Svesaala) 2,3 2
% CV eventa o 30
Comparison of preoperative hemodynamic values (*) revealed that pts
on B had significantly (p c 0.05) lower mean HR and lower diastolic BP.On
repeat HM, ischemia was suppressed in 70% of pts on B. Although 30% of
the control group had CV events, none of the B pts had any cardiac event X2
= 3.94, p = 0
Conclusions: d b effective in sup-
pressing myooerdial ischemia and reduces perioperative CV events in pa-
tients with multivessel u
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In patients at high cardiovascular risk, concomitant hypercholesterolemia
(HC) may reduce the protective effect of antiplatelet drugs such as aspirin
or ticlopidine. Picotamide (Pico) is an orally active antiplateiet agent which
inhibits thromboxane (Tx) A2 synthesis and antagonizes Tx receptors. The
ADEP (Atherosclerotic Disease Evolution by Picotamide) trial had evaluated
the effects on cardiovascular evants of pico, In comparison to placebo, in
2313 patientswith peripheral occlusive vascular disease (POVD). Intheetudy
Population as a whole, Pico reduced c 19% (P=
Logrank test). We conducted, in an “a priori” planned hypotheaia,a eubgroup
analysis to assess the influence of concomitant HC on the protective effect
of pico on cardiovascular events in POVD patients. The efficacy of pioo
was therefore assessad in the ADEP subgroup of HC patients in order to
test if the drug was still effective in this higher risk group. HC was defined
se a serum total cholesterol (TC) greater than 5.2 mmol/L, measured at
baee-lina. In pico treated group, HC patienta were 763 whereaa 262 were
the patients with a TC c 5.2 mmol/L. During the 16-month of follow-up,
there were 76 (9.9%) cardiovascular events (death, myooardial infarction,
stroke, TIA, unstable angina and amputation) in the 763 HC pico-treated
patients as compared to 140 (13.1%) events in the 1066 placebo-treated
subjects (Relative Risk Reduction: 27%, P = 0.03, Mantel-Haenszel Chi-
Square test). In pico-treated patients, no statistical significant difference
on cardiovaeoular event rate were observed among normo and HC patients
(10.6% and 9.9%, respectively). In POVD patients pico effectively reduced
cardiovascular events, irrespective to serum TC levels.
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B.-A. Khaw, R. Virmani, R. Davis, D. Kufe, J. Narula. Dana-Farber Cancer
Institute and Masaechusetts General Hospital, Boston, MA, USA
Brief repetitive episodes of myocardial ischamia, often asymptomatic and not
resulting in significant myocyte necrosis, are the commonest manifestations
of coronary artery disease (CAD). Mammalian cells, in responae to ischemia,
expressa variety of genes to adapt to external stress or inflict further damage.
To evaluate intracellular signaling cascade involving the SAP/JNK kinase in
response to brief episodes of ischemia, LAD coronary artery was occluded
for 5-60 min in rats. SAPk activity (assessed by in vitro immune complex
kinase assays using GST-Jun) increased from 5-10 rein, reached maximum
at 15 min and decreased significantly by 30-60 min. Upon reperfusion after
15 min LAD ligation, the maximal levels of SAPkacfivity were sustained up to
60 min. SAPk induction was also confirmed in neonatal rat myocytea aa well
as H9C2 embryonic rat cerdiocytas. To evaluate sequence of hypoxic SAPk
indur3ion, H9C2 cells were cotransfected with pEBG-SAPk and dominant-
negative mutants (DNM) of SEKI (SEK1 K + R). SEKI K -+ R completely
abrogated SAPk induction. DNM of Racl (N17) and PAK1 with pEBG-SAPk
also inhibited SAPk activation confirming the role of Racl/cdc42Hs and STE-
20 homologies in hypoxic insult to oerdiomyccytes. No activation of MAP or
P-38 MAP kinasa was observed in response to hypoxia.
Cone/usions:The immediate-early activation in brief episodes of myooar-
dial ischemia in CAD may play a role in long-term deleterious effects through
abnormal myocerdial growth response or occurrence of apoptosis. Further,
elucidation of upstream activators of SAPk may help develop intervention
strategies.
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Ischemic preconditioning has a marked infarct siza-reducing effect in hearts.
Pre-ischemic glycogen reduction or glycogenolyfic inhibition may be one of
the mechanisms. Itwas speculated that the compound reducing glycogenolytic
rate by inhibiting a-l ,6-glucosidase of glycogen debranching enzyme in
liver, MOR-14 (N-methyl-l -deoxynojirimycin), may precondition pharmaco-
logically the heart. Thus, it was investigated whether MOR-14 inhibits a-l,6-
glucosidase also in the heart and reduces the infarct size in rabbit hearts
without collateral circulation.
